• Kala Bio posted a net loss of $1.62 million for the three months ended March 31, 2026, narrowing from $8.95 million a year earlier.
• Operating loss improved to $1.8 million as total operating expenses fell to $1.8 million from $10.67 million.
• Research and development expense dropped to $61,000 from $6.06 million, while general and administrative costs declined to $1.74 million from $4.59 million.
• Cash and cash equivalents totaled $1.8 million at March 31, 2026, down from $7.6 million a year earlier.
• Company said it is transitioning toward an AI platform-as-a-service model, focusing on monetizing legacy MSC-S assets and developing the licensed Researgency agentic AI platform, with cash expected to fund operations into the second quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kala Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-062397), on May 15, 2026, and is solely responsible for the information contained therein.